2 weeks Ago By ABMN Staff
CytomX Therapeutics, Inc. ( NASDAQ:CTMX – Free Report ) – Investment analysts at HC Wainwright increased their FY2024 earnings estimates for CytomX Therapeutics in a research note issued to investors on Monday, November 11th. HC Wainwright analyst M.
Kapoor now expects that the biotechnology company will post earnings of $0.14 per share for the year, up from their prior forecast of ($0.11).
HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for CytomX Therapeutics’ current full-year earnings is ($0.13) per share.
HC Wainwright also issued estimates for CytomX Therapeutics’ Q4 2024 earnings at ($0.01) EPS, Q1 2025 earnings at ($0.02) EPS, Q2 2025 earnings at ($0.
03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.04) EPS and FY2025 earnings at ($0.
12) EPS. CytomX Therapeutics Stock Down 1.0 % Shares of NASDAQ:CTMX opened at $1.
00 on Wednesday. The stock has a market cap of $78.26 million, a PE ratio of 5.
94 and a beta of 1.06. CytomX Therapeutics has a 12-month low of $0.
98 and a 12-month high of $5.85. The business has a 50 day moving average of $1.
13 and a 200-day moving average of $1.46. Institutional Inflows and Outflows Institutional investors and hedge funds have recently added to or reduced their stakes in the company.
SG Americas Securities LLC acquired a new position in shares of CytomX Therapeutics in the first quarter valued at about $57,000. US Bancorp DE bought a new stake in CytomX Therapeutics in the 3rd quarter valued at about $40,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of CytomX Therapeutics during the 1st quarter worth approximately $124,000.
XTX Topco Ltd increased its holdings in shares of CytomX Therapeutics by 382.6% during the second quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 48,033 shares during the period.
Finally, Forefront Analytics LLC raised its position in shares of CytomX Therapeutics by 206.7% in the second quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 43,176 shares in the last quarter.
67.77% of the stock is owned by institutional investors and hedge funds. CytomX Therapeutics Company Profile ( Get Free Report ) CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment.
The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. Read More Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
